Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

G-CSF improves safety when you start the day after autologous transplant in multiple myeloma.

Sborov DW, Cho YK, Cottini F, Hade EM, Lamprecht M, Tackett K, Sharma N, Williams N, Li J, Devine S, Poi M, Phelps MA, Hofmeister CC.

Leuk Lymphoma. 2017 Dec;58(12):2947-2951. doi: 10.1080/10428194.2017.1318436. Epub 2017 May 16. No abstract available.

PMID:
28509594
2.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC.

Leuk Lymphoma. 2017 Oct;58(10):2310-2318. doi: 10.1080/10428194.2017.1298751. Epub 2017 Mar 7.

PMID:
28270022
3.

Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA.

Clin Pharmacol Ther. 2017 Sep;102(3):511-519. doi: 10.1002/cpt.644. Epub 2017 May 26.

PMID:
28160288
4.

Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.

Poi MJ, Li J, Sborov DW, VanGundy Z, Cho YK, Lamprecht M, Pichiorri F, Phelps MA, Hofmeister CC.

Mol Carcinog. 2017 Jul;56(7):1722-1732. doi: 10.1002/mc.22626. Epub 2017 Feb 16.

PMID:
28150872
5.

Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F.

Mol Cancer Ther. 2016 May;15(5):830-41. doi: 10.1158/1535-7163.MCT-15-0240-T. Epub 2016 Jan 25.

6.

HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide.

Canella A, Cordero Nieves H, Sborov DW, Cascione L, Radomska HS, Smith E, Stiff A, Consiglio J, Caserta E, Rizzotto L, Zanesi N, Stefano V, Kaur B, Mo X, Byrd JC, Efebera YA, Hofmeister CC, Pichiorri F.

Oncotarget. 2015 Oct 13;6(31):31134-50. doi: 10.18632/oncotarget.5290.

7.

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.

Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC.

Br J Haematol. 2015 Oct;171(1):74-83. doi: 10.1111/bjh.13527. Epub 2015 Jun 8.

8.

A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC.

Clin Cancer Res. 2014 Dec 1;20(23):5946-55. doi: 10.1158/1078-0432.CCR-14-1404. Epub 2014 Oct 7.

9.

Investigational cancer drugs targeting cell metabolism in clinical development.

Sborov DW, Haverkos BM, Harris PJ.

Expert Opin Investig Drugs. 2015 Jan;24(1):79-94. Epub 2014 Sep 16.

10.

How I manage patients with acquired haemophilia A.

Sborov DW, Rodgers GM.

Br J Haematol. 2013 Apr;161(2):157-65. doi: 10.1111/bjh.12228. Epub 2013 Feb 4. Review.

PMID:
23373521
11.

Acquired hemophilia a: a current review of autoantibody disease.

Sborov DW, Rodgers GM.

Clin Adv Hematol Oncol. 2012 Jan;10(1):19-27. Review.

PMID:
22398803

Supplemental Content

Loading ...
Support Center